The short answer
Compounding is a lawful and regulated part of pharmacy practice in the United States, and it has been for a long time. Whether a particular personalized compounded semaglutide product is lawful depends on whether the pharmacy that made it and the prescription it was made for meet the conditions federal and state law set, and those conditions changed in practice when the FDA declared the semaglutide shortage over in 2025. This guide sets out the framework as the FDA explains it on its own pages, what changed with the shortage, and what the FDA has said in 2026, so that the question has a real answer rather than a slogan.
Two things this guide is not. It is not legal advice, and it is not medical advice. It reports what the FDA’s published pages say as of the dates given. Personalized Compounded semaglutide is not FDA-approved and is not equivalent to Wegovy® or Ozempic®, and your licensed provider is the person to ask about whether treatment is appropriate for you.
Two sections of one law
The FDA’s page on compounding laws and policies explains that federal law addresses human drug compounding in two sections of the Federal Food, Drug and Cosmetic Act. Section 503A describes the conditions under which drugs compounded by a licensed pharmacist in a state-licensed pharmacy or federal facility, or by a physician, are exempt from three of the law’s requirements: FDA approval before marketing, current good manufacturing practice, and labelling with adequate directions for use. One of the conditions the page names is that the drugs must be compounded on the basis of a valid patient-specific prescription.
Section 503B was added in 2013 by the Drug Quality and Security Act, which the page says Congress passed in response to a 2012 outbreak in which contaminated drugs compounded by one pharmacy led to more than 750 cases of infection and more than 60 deaths in 20 states. Section 503B created outsourcing facilities, a voluntary category of compounder that is subject to current good manufacturing practice requirements, is inspected by the FDA on a risk-based schedule, must report adverse events, and may distribute compounded drugs either on a patient-specific prescription or on a provider’s order for office stock.
The FDA’s questions and answers page describes who watches whom. State boards of pharmacy generally have primary responsibility for the day to day oversight of state-licensed pharmacies that are not registered as outsourcing facilities, while the FDA conducts surveillance and for-cause inspections of them and primarily oversees the outsourcing facilities. Whichever section applies, the page says, other federal law also applies, including the provisions on insanitary conditions.
Bodi Envi’s prescriptions go to third party U.S. 503A licensed compounding pharmacies, and Bodi Envi publishes that applicable state boards of pharmacy regulate and inspect those pharmacies and that their sterile compounding practices are subject to applicable U.S. Pharmacopeia standards.
The “essentially a copy” rule
The condition that matters most for GLP-1 medications is the one about copies. The FDA’s page on compounding when drugs are on the shortage list explains that section 503A restricts compounded drugs that are essentially copies of commercially available drugs, though certain amounts are permissible as long as the compounding is not done regularly or in inordinate amounts, and that outsourcing facilities are restricted from making essentially a copy of an approved drug at all.
The FDA’s April 1, 2026 update on GLP-1 compounding spells out how it reads the rule. It says the agency intends to consider a compounded product essentially a copy of a commercially available product when it has the same active ingredient in the same, similar or an easily substitutable strength, and the commercially available product can be used by the same route of administration prescribed for the compounded one. The exception is a prescriber’s determination, documented, that the compounded product contains a change that produces a significant difference for an identified individual patient. The update gives an example: a product combining semaglutide with vitamin B12 may still be considered essentially a copy when it is given by the same route and its strengths are within 10 percent of the approved products. It also states that, at this time, the FDA does not intend to take action against a compounder that fills four or fewer prescriptions of such a product in a calendar month.
Whether a given personalized compounded semaglutide prescription falls inside or outside that rule is a determination about that prescription, made and documented by the prescriber. It is not something a patient can assess from the outside, and this guide does not make it for anyone.
What the shortage changed, and what its end changed
A drug on the FDA’s drug shortage list is treated differently. The shortage page explains that a drug is not considered commercially available while it is on the list, so the limitation on essentially copies does not apply, and an outsourcing facility may compound it from bulk substance. All other conditions of 503A still have to be met, including the patient-specific prescription.
Semaglutide injection products were on that list from 2022, and the compounding of GLP-1 medications grew up in that window. The FDA’s timeline, on its page on GLP-1 supply, runs as follows. On February 21, 2025 the FDA determined that the shortage of semaglutide injection products was resolved, having confirmed with the manufacturer that its stated availability and capacity could meet present and projected national demand. To avoid disrupting treatment, the agency said it did not intend to take action against 503A pharmacies compounding semaglutide that was essentially a copy of an approved product until April 22, 2025, or against outsourcing facilities until May 22, 2025. After a district court denied a preliminary injunction on April 24, 2025, the FDA’s page states that the period of enforcement discretion for state-licensed pharmacies and physicians under 503A has ended. Tirzepatide had followed the same path earlier: its shortage was declared resolved, the 503A discretion period ended in March 2025 after a court decision on March 5, and the outsourcing facility period ended on March 19, 2025.
Read plainly, the end of the shortage removed the exception. It did not create a new prohibition on compounding, and it did not change the ordinary conditions of 503A. What it did was put semaglutide back into the category of commercially available drugs, so that the essentially a copy rule applies again in full. The FDA’s April 1, 2026 update reminds compounders of exactly that, and states that tirzepatide and semaglutide do not currently appear on the 503B bulks list or on the drug shortage list.
What the FDA said in 2026
Two 2026 statements bear on the question. The first is the April 1, 2026 update already described, which is addressed to compounders and restates the conditions for the 503A and 503B exemptions, the reading of essentially a copy, and the four or fewer prescriptions position.
The second is a press announcement dated April 30, 2026, in which the FDA said it was proposing to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, having found no clinical need for outsourcing facilities to compound these drugs from bulk substances. The announcement explains that outsourcing facilities generally cannot compound from bulk substances unless the substance is on that list or the drug is in shortage, and invites comments until June 29, 2026 before a final determination. That proposal concerns 503B outsourcing facilities, which is not the kind of pharmacy Bodi Envi’s prescriptions go to; it says nothing directly about compounding under 503A, and as of the date this guide was checked the FDA’s pages describe it as a proposal.
Separately, the FDA’s statement on its concerns with unapproved GLP-1 drugs, dated September 1, 2026, restates the agency’s position on use: compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug, patients should obtain a prescription from a licensed provider and fill it at a state-licensed pharmacy, and the agency has issued warning letters over illegally marketed semaglutide and tirzepatide, including products falsely labelled for research purposes. That statement also names two substances, retatrutide and cagrilintide, that it says cannot be used in compounding under federal law and are not components of any approved drug.
Legal is not the same as approved
It is worth separating two questions that the word legal tends to blur. Whether a compounded product may lawfully be made and dispensed is a question about the pharmacy, the prescription and the conditions above. Whether it has been shown safe and effective is a different question, and the FDA’s answer is that it has not been reviewed. Its human drug compounding page states that compounded drugs are not FDA approved, which means the agency does not review their safety, effectiveness or quality before they are marketed, and the questions and answers page adds that unnecessary use of compounded drugs may expose patients to potentially serious health risks because poor compounding practices can result in contamination or a drug with too much or too little active ingredient.
A lawfully compounded product, in other words, still carries none of the assurance an approved product does. Bodi Envi states this on every page that discusses compounded treatment: compounded personalized semaglutide is not FDA-approved and is not equivalent to FDA-approved products.
What this means for a patient
For someone considering personalized compounded semaglutide, the FDA’s framework translates into a short list of things a legitimate arrangement must have. A licensed prescriber who has evaluated you and written a patient-specific prescription, since 503A compounding is not permitted without one. A state-licensed pharmacy that is overseen by its state board, and whose name and contact details appear on your prescription label. A prescriber’s clinical reasoning for a compounded product rather than an approved one, which the FDA’s position on when compounded drugs should be used implies and which its essentially a copy reading makes a matter of documentation. And an honest description of the product, since the FDA lists a claim that a compounded drug is the same as an approved one among the warning signs of an unsafe seller.
Bodi Envi’s programs are built on the first two: an online health assessment reviewed by a licensed provider through Wasef Health, PC for applicable programs, a prescription only if the provider determines treatment is appropriate, and dispensing by a third party U.S. 503A licensed compounding pharmacy, with VialsRx the current partner for applicable GLP-1 prescriptions and availability varying by program and location. Bodi Envi publishes that eligibility, prescribed medication, fulfilment pharmacy and availability vary by individual clinical evaluation, patient location and program, which is the honest way to describe an arrangement that depends on state law and clinical judgment.
This guide is general information, not legal or medical advice. It reports the FDA’s published pages as of the dates given, and those pages change; the FDA’s own site is the authority for the current position. Personalized Compounded semaglutide is not FDA-approved, and whether treatment of any kind is appropriate for you is a decision for your licensed provider.